Literature DB >> 11358720

Drug-induced urticaria.

F Cousin1, K Philips, B Favier, J Bienvenu, J F Nicolas.   

Abstract

The occurrence of acute urticaria during treatment with drugs is a frequent event which poses two problems: 1) is the urticaria connected with the drug administration or with the underlying pathology which led to the prescription of the drug; 2) is the urticaria allergic in origin, i.e. due to specific immunity triggers, in particular IgE directed against the drug, or is the urticaria pseudo-allergic in origin, i.e. due to non-specific activation of mastocytes [1]? This question is of major importance because allergic events caused by IgE are potentially fatal while pseudo-allergic events are only rarely life-threatening. In this article we will not deal with contact urticaria where the cause is easily identifiable [2].

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358720

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  4 in total

1.  Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.

Authors:  Cristina Guijarro; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Neurol Sci       Date:  2010-10-02       Impact factor: 3.307

2.  Allergic reaction related to ramipril use: a case report.

Authors:  Renata C Alencar; Roberta A Cobas; Marília B Gomes
Journal:  Diabetol Metab Syndr       Date:  2010-01-20       Impact factor: 3.320

Review 3.  Pathophysiology of urticaria.

Authors:  Ana Hennino; Fréderic Bérard; Isabelle Guillot; Nathalie Saad; Auore Rozières; Jean-François Nicolas
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

Review 4.  Chronic urticaria in adults: state-of-the-art in the new millennium.

Authors:  Paulo Ricardo Criado; Roberta Facchini Jardim Criado; Celina Wakisaka Maruta; Vitor Manoel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.